Document:

Common Stock Purchase Warrant

 EXHIBIT 4.38.1 
 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM,
OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL
BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION
THAT IS AN “ACCREDITED INVESTOR” AS THAT TERM IS DEFINED IN RULE 501(A) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES. 
 Warrant No. 6 
 COMMON STOCK PURCHASE WARRANT 
 To Purchase 324,500 Shares of Common Stock of 
 SYNOVA HEALTHCARE GROUP, INC.

 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Galt Industries, Inc., a
Delaware corporation (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after January 12, 2007 (the “Initial Exercise
Date”) and on or prior to the close of business on January 12, 2012 (the “Termination Date”) but not thereafter, to subscribe for and purchase from, Synova Healthcare Group, Inc. (the “Company”), up to
324,500 shares (the “Warrant Shares”) of Common Stock, par value $0.001 per share, of the Company (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the
Exercise Price, as defined in Section 2(b). 
 Section 1. Definitions. Capitalized terms used and not otherwise
defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the “Purchase Agreement”), dated as of January 12, 2007, among the Company and the purchasers signatory thereto. 
 Section 2. Exercise. 
 a) Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination
Date by delivery to the Company of a 

 
duly executed facsimile copy of the Notice of Exercise Form annexed hereto (or such other office or agency of the Company as it may designate by notice in
writing to the registered Holder at the address of such Holder appearing on the books of the Company); and, within 3 Trading Days of the date said Notice of Exercise is delivered to the Company, the Company shall have received payment of the
aggregate Exercise Price of the shares thereby purchased by wire transfer or cashier’s check drawn on a United States bank. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant
to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within 3 Trading Days of
the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding
number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases.
The Company shall deliver any objection to any Notice of Exercise Form within 2 Trading Days of receipt of such notice. In the event of any dispute or discrepancy, the records of the Holder shall be controlling and determinative in the absence of
manifest error. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares
available for purchase hereunder at any given time may be less than the amount stated on the face hereof. 
 b) Exercise
Price. The exercise price per share of the Common Stock under this Warrant shall be $1.00, subject to adjustment hereunder (the “Exercise Price”). 
 c) Cashless Exercise. If at any time after the date of issuance of this Warrant there is no effective Registration Statement
registering, or no current prospectus available for, the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive a
certificate for the number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where: 
  

	 	(A)	= the daily volume weighted average price of the Common Stock (as reported by Bloomberg, L.P.) (“VWAP”) for the five Trading Days immediately preceding the date of
such election; 

  

	 	(B)	= the Exercise Price of this Warrant, as adjusted; and 

  

	 	(X)	= the number of Warrant Shares issuable upon exercise of this Warrant in accordance with the terms of this Warrant by means of a cash exercise rather than a cashless exercise.

  

 2 

 Notwithstanding anything herein to the contrary, on the Termination Date, this Warrant
shall be automatically exercised via cashless exercise pursuant to this Section 2(c). 
  

	 	d)	Intentionally omitted. 

  

	 	e)	Mechanics of Exercise. 

 i.
Authorization of Warrant Shares. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant, be
duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such
issue). 
 ii. Delivery of Certificates Upon Exercise. Certificates for shares purchased hereunder shall be
transmitted by the transfer agent of the Company to the Holder by crediting the account of the Holder’s prime broker with the Depository Trust Company through its Deposit Withdrawal Agent Commission (“DWAC”) system if the
Company is a participant in such system, and otherwise by physical delivery to the address specified by the Holder in the Notice of Exercise within three Trading Days from the delivery to the Company of the Notice of Exercise Form, surrender of this
Warrant (if required) and payment of the aggregate Exercise Price as set forth above (if applicable) (“Warrant Share Delivery Date”). This Warrant or any portion thereof shall be deemed to have been exercised on the date the
Exercise Notice is delivered to the Company. The Warrant Shares shall be deemed to have been issued, and Holder or any other person so designated to be named therein shall be deemed to have become a holder of record of such shares for all purposes,
as of the date the Warrant has been exercised by payment to the Company of the Exercise Price (or by cashless exercise, if permitted) and any taxes required to be paid by the Holder by the proviso of Section 2(e)(viii) below have been paid.

 iii. Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall,
at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the certificate or certificates representing Warrant Shares, deliver to Holder a new Warrant evidencing the rights of Holder to purchase the
unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant. 
 iv. Rescission Rights. If the Company fails to cause its transfer agent to transmit to the Holder a certificate or certificates representing the 

  

 3 

 
Warrant Shares pursuant to this Section 2(e)(ii) by the Warrant Share Delivery Date (a “Delivery Failure”), then the Holder will have
the right to rescind such exercise at any time prior to delivery of such certificate(s). The Company shall, within two Trading Days, notify the Holder and the holders of each of the other warrants issued under the Purchase Agreement should a
Delivery Failure occur with respect to the Warrant or any other such warrant. 
 v. Buy-In. If after a Delivery
Failure occurs and prior to the receipt of such Warrant Shares, the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder
anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (1) pay in cash to the Holder the amount by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the
shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (A) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue by (B) the closing bid
price of the Common Stock on the Exercise Date and (2) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored or deliver to the Holder the number
of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect
of the Buy-In. 
 vi. Liquidated Damages. Upon a Delivery Failure, then the Company shall pay the Holder damages for
each Trading Day of such Conversion Failure in an amount equal to 1.5% of the product of (A) the sum of the number of Warrant Shares not issued to the Holder on or prior to third (3rd) Trading Day after the Conversion Date and to which the
Holder is entitled, and (B) the Closing Price of the Common Stock on such date. 
 vii. No Fractional Shares or
Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which Holder would otherwise be entitled to purchase upon such exercise, the Company shall at
its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share. 
 viii. Charges, Taxes and Expenses. Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any
issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall be paid by the 

  

 4 

 
Company, and such certificates shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided,
however, that in the event certificates for Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by
the Holder; and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. 
 ix. Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof. 
 Section 3. Certain Adjustments. 
 a) Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (A) pays a stock dividend or otherwise make a distribution or distributions on shares of its Common Stock or
any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (B) subdivides outstanding
shares of Common Stock into a larger number of shares, (C) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (D) issues by reclassification of shares of the Common
Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately
before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted. Any adjustment
made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date
in the case of a subdivision, combination or re-classification. 
 b) Subsequent Equity Sales. 
 i. While any portion of this Warrant is outstanding, if the Company issues any shares of Common Stock, or the Company or any subsidiary
thereof issues any Common Stock Equivalents entitling any Person to acquire shares of Common Stock, at a price per share less than the Exercise Price (if the holder of the Common Stock or Common Stock Equivalent so issued shall at any time, whether
by operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights issued in connection with such issuance, be entitled to receive shares of Common Stock
at a price less than the Exercise Price, such issuance shall be deemed to have occurred for less than the Exercise Price), then, in each 

  

 5 

 
case the Exercise Price shall be reduced to mirror such lower price. Such adjustment shall be made whenever such Common Stock or Common Stock Equivalents are
issued. The Company shall notify the Holder in writing, no later than the Trading Day following the issuance of any Common Stock or Common Stock Equivalent subject to this section, indicating therein the applicable issuance price, or of the
applicable reset price, exchange price, conversion price and other pricing terms. 
 ii. If, at any time while this Warrant
is outstanding, the Company or any subsidiary thereof issues Common Stock Equivalents at a price per share that floats or resets or otherwise varies or is subject to adjustment based on market prices of the Common Stock (a “Floating Price
Security”), then for purposes of applying the preceding paragraph in connection with any subsequent exercise, the Exercise Price will be determined separately on each date the Warrant is exercised (the “Exercise Date”) and
will be deemed to equal the lowest price per share at which any holder of such Floating Price Security is entitled to acquire shares of Common Stock on or prior to such Exercise Date (regardless of whether any such holder actually acquires any
shares on such date). 
 iii. Notwithstanding the foregoing, no adjustment will be made under this Section 3(b) as a
result of an Exempt Issuance. An “Exempt Issuance” means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Company pursuant to any employment agreement, equity incentive plan or option
plan approved by stockholders of the Company or duly adopted by a majority of the non-employee members of the Board of Directors of the Company or a majority of the members of a committee of non-employee directors established for such purpose,
(b) securities upon the exercise or exchange of or conversion of any Securities issued hereunder and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this
Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise, exchange or conversion price of any such securities, and (c) securities
issued pursuant to the Allendale Acquisition Agreement. 
 iv. Simultaneously with any adjustment to the Exercise Price
pursuant to this Section 3(b), the number of Warrant Shares that may be purchased upon exercise of this Warrant shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for
the adjusted number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment. 
 c) Subsequent Rights Offerings. If the Company, at any time while the Warrant is outstanding, shall issue any rights, options or warrants to all holders of 

  

 6 

 
Common Stock (and not to the Holder) entitling them to subscribe for or purchase shares of Common Stock at a price per share less than the VWAP at the record
date mentioned below, then the Exercise Price shall be multiplied by a fraction, of which the denominator shall be the number of shares of the Common Stock outstanding on the date of issuance of such rights or warrants plus the number of additional
shares of Common Stock offered for subscription or purchase, and of which the numerator shall be the number of shares of the Common Stock outstanding on the date of issuance of such rights or warrants plus the number of shares which the aggregate
offering price of the total number of shares so offered (assuming receipt by the Company in full of all consideration payable upon exercise of such rights, options or warrants) would purchase at such VWAP. Such adjustment shall be made whenever such
rights or warrants are issued, and shall become effective immediately after the record date for the determination of stockholders entitled to receive such rights, options or warrants. 
 d) Pro Rata Distributions. If the Company, at any time prior to the Termination Date, shall distribute to all holders of Common
Stock (and not to the Holder of the Warrant) evidences of its indebtedness or assets (including cash and cash dividends) or rights or warrants to subscribe for or purchase any security other than the Common Stock, then in each such case the Exercise
Price shall be adjusted by multiplying the Exercise Price in effect immediately prior to the record date fixed for determination of stockholders entitled to receive such distribution by a fraction of which the denominator shall be the VWAP
determined as of the record date mentioned above, and of which the numerator shall be such VWAP on such record date less the then per share fair market value at such record date of the portion of such assets or evidence of indebtedness so
distributed applicable to one outstanding share of the Common Stock as determined by the Board of Directors in good faith. In either case the adjustments shall be described in a statement provided to the Holder of the portion of assets or evidences
of indebtedness so distributed or such subscription rights applicable to one share of Common Stock. Such adjustment shall be made whenever any such distribution is made and shall become effective immediately after the record date mentioned above.

 e) Fundamental Transaction. If, at any time while this Warrant is outstanding, (A) the Company effects any
merger or consolidation of the Company with or into another Person, (B) the Company effects any sale of all or substantially all of its assets in one or a series of related transactions, (C) any tender offer or exchange offer (whether by
the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to tender or exchange their shares for other securities, cash or property, or (D) the Company effects any reclassification of the Common Stock
or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (in any such case, a “Fundamental Transaction”), then, upon any subsequent
exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder,
(a) upon exercise of this Warrant, the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate
Consideration”) receivable upon or as a result of such reorganization, reclassification, 

  

 7 

 
merger, consolidation or disposition of assets by a Holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to
such event or (b) cash equal to the value of this Warrant as determined in accordance with the Black-Scholes option pricing formula. For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to
apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate
Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental
Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any
successor to the Company or surviving entity in such Fundamental Transaction shall issue to the Holder a new warrant consistent with the foregoing provisions and evidencing the Holder’s right to exercise such warrant into Alternate
Consideration. The terms of any agreement pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this Section 3(e) and insuring that this
Warrant (or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous to a Fundamental Transaction. 
 f) Change of Control. Upon the occurrence or entering into by the Company or any subsidiary, or consummation of, any Change of Control, then, the Holder shall have the right to receive, for each Warrant Share
that would have been issuable upon such exercise immediately prior to the occurrence of such Change of Control, at the option of the Holder, (a) upon exercise of the Warrant, the number of shares of common stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration receivable upon or as a result of such reorganization, reclassification, merger, consolidation or disposition of assets by an Investor of the number
of shares of Common Stock for which the Warrant is exercisable immediately prior to such event or (b) cash equal to the value of the Warrant as determined in accordance with the Black-Scholes option pricing formula. 
 g) Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as
the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and
outstanding. 
 h) Notice to Holders. 
 i. Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the
Company shall promptly mail to each Holder a notice setting forth the Exercise Price after such adjustment and setting forth a brief statement of the facts requiring such adjustment. 
  

 8 

 ii. Notice to Allow Exercise by Holder. If (A) the Company shall declare a
dividend (or any other distribution in whatever form) on the Common Stock; (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock; (C) the Company shall authorize the granting to all
holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights; (D) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, of any compulsory share exchange whereby the Common Stock is converted into other
securities, cash or property; (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company; then, in each case, the Company shall cause to be mailed to the Holder at its last
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the
purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants
are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of
record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such
notice or any defect therein or in the mailing thereof shall not affect the validity of the corporate action required to be specified in such notice. The Holder will be entitled to exercise this Warrant during the 20-day period commencing on the
date of such notice to the effective date of the event triggering such notice, provided that this Warrant is otherwise exercisable. 
 Section 4. Transfer of Warrant. 
 a) Transferability. Subject to compliance with any
applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights)
are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the
Holder or its agent or attorney. Upon such surrender the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees and in the denomination or denominations specified in such instrument of assignment, and
shall issue to the assignor a new Warrant evidencing the portion of this Warrant not 

  

 9 

 
so assigned, and this Warrant shall promptly be cancelled. A Warrant, if properly assigned, may be exercised by a new holder for the purchase of Warrant
Shares without having a new Warrant issued. 
 b) New Warrants. This Warrant may be divided or combined with other
Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to
compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in
accordance with such notice. 
 c) Warrant Register. The Company shall register this Warrant, upon records to be
maintained by the Company for that purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for
the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. 
 d) Transfer Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be registered pursuant to an effective
registration statement under the Securities Act and under applicable state securities or blue sky laws, the Company may require, as a condition of allowing such transfer (i) that the Holder or transferee of this Warrant, as the case may be,
furnish to the Company a written opinion of counsel (which opinion shall be in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect that such transfer may be made without registration under the
Securities Act and under applicable state securities or blue sky laws, (ii) that the holder or transferee execute and deliver to the Company a written certification that warrants that it is acquiring the Warrants for its own account and not
with a view to public distribution and as to the substance of the matters described in Section 3.2(e) of the Purchase Agreement, and (iii) that the transferee be an “accredited investor” as defined in Rule 501(a)(1), (a)(2),
(a)(3), (a)(7), or (a)(8) promulgated under the Securities Act or a “qualified institutional buyer” as defined in Rule 144A(a) under the Securities Act. 
 Section 5. Miscellaneous. 
 a) No Rights as Shareholder Until Exercise. This Warrant does not entitle the Holder to any voting rights or other rights as a shareholder of the Company prior to the exercise hereof as set forth in
Section 2(e)(ii). 
 b) Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt
by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security
reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock 

  

 10 

 
certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of
such Warrant or stock certificate. 
 c) Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking
of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day. 
 d) Authorized Shares. The Company covenants that during the period the Warrant is outstanding, it will reserve from its authorized
and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute
full authority to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for the Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take
all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be
listed. 
 Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including,
without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or
performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth
in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (a) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase
in par value, (b) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant, and (c) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant. 
 Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in
the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof. 
 e) Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be
determined in accordance with the provisions of the Purchase Agreement. 
  

 11 

 f) Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the
exercise of this Warrant, if not registered, will have restrictions upon resale imposed by state and federal securities laws. 
 g) Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice Holder’s rights, powers or remedies,
notwithstanding the fact that all rights hereunder terminate on the Termination Date. If the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall
pay to Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by Holder in collecting any amounts due pursuant
hereto or in otherwise enforcing any of its rights, powers or remedies hereunder. 
 h) Notices. Any notice, request or
other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement. 
 i) Limitation of Liability. No provision hereof, in the absence of any affirmative action by Holder to exercise this Warrant to
purchase Warrant Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability of Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by
the Company or by creditors of the Company. 
 j) Remedies. Holder, in addition to being entitled to exercise all
rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach
by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate. 
 k) Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of all Holders from time to time of this Warrant
and shall be enforceable by any such Holder or holder of Warrant Shares. 
 l) Amendment. This Warrant may be modified
or amended or the provisions hereof waived with the written consent of the Company and the Holder. 
 m) Severability.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision
shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant. 
  

 12 

 n) Headings. The headings used in this Warrant are for the convenience of
reference only and shall not, for any purpose, be deemed a part of this Warrant. 
 ******************** 
  

 13 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly
authorized. 
 Dated: January 12, 2007 
  

			
	SYNOVA HEALTHCARE GROUP, INC.
		
	By:	 	/s/ Stephen E. King
	Name:	 	Stephen E. King
	Title:	 	Chairman and Chief Executive Officer

  

 14 

 NOTICE OF EXERCISE OF COMMON STOCK WARRANT 
 TO: SYNOVA HEALTHCARE GROUP, INC. 
 (1) The undersigned
hereby elects to purchase                      Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any. 
 (2) Payment
shall take the form of (check applicable box): 
  

	 	 ̈	in lawful money of the United States; or 

  

	 	 ̈	[if permitted] the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect
to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c). 

 (3) Please issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name as is specified below: 
  

	
	______________________________

 The Warrant Shares shall be delivered to the following DWAC Account Number or by physical delivery of a
certificate to: 
  

	
	______________________________
	______________________________
	______________________________

 (4) Accredited Investor. The undersigned is an “accredited investor” as defined
in Regulation D promulgated under the Securities Act of 1933, as amended. 
  

	
	[SIGNATURE OF HOLDER]
	
	Name of Investing
Entity:                                       
                                        
                                        
                                        
                                        
        
	Signature of Authorized Signatory of Investing
Entity:                                       
                                        
                                        
                                   
	Name of Authorized
Signatory:                                      
                                        
                                        
                                        
                                      
 
	Title of Authorized
Signatory:                                      
                                        
                                       
                                        
                                        
   
	Date:                                     
                                        
                                        
                                        
                                        
                                        
          

  

 15 

 ASSIGNMENT FORM 
 (To assign the foregoing warrant, execute 
 this form and supply required information. 
 Do not use this form to exercise the warrant.) 
 FOR VALUE RECEIVED, [            ] all of or
[                    ] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to 
                                       
                                        
                                        
                                   whose address is 
                                       
                                        
                                        
                                        
                                . 
                                       
                                        
                                        
                                        
                                        
                                        
         
 Dated:
                    ,              
  

	
	Holder’s Signature:
                                        
            

  

	
	Holder’s Address:
                                        
              

  

	
	                                      
                                        
                                        
                                        
                                        
                                        
            

  

	
	Signature Guaranteed:                                  
                                        
                                        
                                        
                                        
                    

 NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the
Warrant, without alteration or enlargement or any change whatsoever, and must be guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of
authority to assign the foregoing Warrant. 
  

 16Escrow Agreement

 Exhibit 10.32 
 ESCROW AGREEMENT 
 THIS ESCROW
AGREEMENT is made and entered into as of this 12th day of January, 2007, by and among Synova Healthcare Group, Inc.,
a Nevada corporation (“Parent”), George Votis, an individual with offices located at 655 Madison Avenue, 20th Floor, New York, NY 10021 (“Stockholders’ Representative”), Galt Industries, Inc., a Delaware corporation with offices located at 655 Madison Avenue, 20th Floor, New York, NY 10021 (“Galt”), Gene Detroyer, an individual residing at 357 East 57th Street, Apt. 14B, New York, NY 10022, (“Detroyer”), Robert Staab, an individual residing at 30 Neck Road, Old Lyme, CT 06372
(“Staab” and, together with Galt and Detroyer, collectively, the “Indemnifying Shockholders”) and Blank Rome LLP (the “Escrow Agent”). 
 Background 
 A. Parent, Synova
2006 Acquisition Corp. (“Merger Sub”), Allendale Pharmaceuticals, a Delaware corporation (“API”) and the Indemnifying Stockholders have entered into an Agreement and Plan of Merger, dated as of
January 12, 2007 (the “Merger Agreement”), as a result of which Merger Sub has been or shall be merged with and into API (the “Merger”). 
 B. The Merger Agreement requires that One Million (1,000,000) of the shares of Parent’s common stock, par value $.001 per share
(“Parent Common Stock”) be deposited with the Escrow Agent (“Indemnity Escrow Shares”) as security for certain adjustments to the Merger Consideration (as defined in the Merger Agreement) and for
certain indemnification obligations of the Indemnifying Stockholders. 
 C. The Indemnity Escrow Shares, together with any additional
property required to be deposited with the Escrow Agent under this Escrow Agreement, constitute the “Escrow Assets” to be held and distributed in accordance with the terms of this Escrow Agreement. 
 D. Stockholders’ Representative has been appointed as the agent of all Indemnifying Stockholders, with the authority to enter into, and act on
behalf of such holders for purposes of, this Escrow Agreement. 
 Agreement 
 NOW, THEREFORE, the parties hereto, in consideration of the mutual covenants herein contained and for other good and valuable consideration, the receipt
of which is hereby acknowledged, and intending to be legally bound hereby, covenant and agree as follows: 
 1. Appointment of the Escrow
Agent. Parent and Stockholders’ Representative, on behalf of the Indemnifying Stockholders, hereby appoint the Escrow Agent to serve as escrow agent, subject to and in accordance with the provisions of this Escrow Agreement. The Escrow
Agent hereby accepts such appointment. 
  

 2. Formation of Escrow. Simultaneously with the execution of this Escrow Agreement, Parent has
delivered or caused to be delivered to the Escrow Agent certificates evidencing an aggregate of One Million (1,000,000) shares of Parent Common Stock, registered in the names of the Indemnifying Stockholders as specified on Schedule A
attached to this Escrow Agreement. The Escrow Agent hereby acknowledges receipt of the Indemnity Escrow Shares. In accordance with the Merger Agreement, the certificates representing the Indemnity Escrow Shares have been or shall be endorsed by the
respective Stockholders in blank or accompanied by a separate stock power executed in blank for transfer. 
 3. Duties of the Escrow
Agent. 
 (a) General. The Escrow Agent shall hold, keep custody of, and dispose of the Indemnity Escrow Shares and other Escrow
Assets only in accordance with the terms and conditions of this Escrow Agreement. 
 (b) Statements of Account. The Escrow Agent
shall, as requested by either Parent or the Stockholders’ Representative from time to time, provide Parent and the Stockholders’ Representative with statements reflecting the status of the Escrow Assets. 
 4. Ownership of Escrow Shares; Voting Rights. Pending distribution of Indemnity Escrow Shares in accordance with this Escrow Agreement, each
Indemnifying Stockholder shall be the record and legal owner of the respective number of Indemnity Escrow Shares set forth as to that Indemnifying Stockholder on Schedule A attached to this Escrow Agreement, and shall have all voting rights
with respect to the Indemnity Escrow Shares. 
 5. Distributions in Respect of Indemnity Escrow Shares. 
 (a) Any additional certificates, rights, securities or interests delivered in respect of the Indemnity Escrow Shares while held under this Escrow
Agreement as a result of any stock dividend, recapitalization, stock split, consolidation of shares, reclassification, merger, consolidation or reorganization by Parent shall be delivered to the Escrow Agent (and endorsed for transfer, if
applicable) and shall constitute part of the Escrow Assets. 
 (b) Any cash dividends paid on account of Indemnity Escrow Shares or other
Escrow Assets while held under this Escrow Agreement shall be paid by Parent to the Indemnifying Stockholders as stockholders of record. 
 6. Distribution of Escrow Assets. 
 (a) For purposes of this Escrow Agreement, if no claim for either (i) adjustment of
the Merger Consideration pursuant to Section 1.4 of the Merger Agreement, or (ii) Indemnifiable Losses pursuant to Article VII of the Merger Agreement (each such claim under clause (i) or (ii) being a
“Claim”), is made by Parent on or before the twelve (12) month 

 
anniversary (the “Release Date”) of the date hereof, then the Escrow Agent shall distribute the Indemnity Escrow Shares, within five days, to the
respective Indemnifying Stockholders as specified on Schedule A, together with any other Escrow Assets which were derived therefrom or distributed on account thereof. 
 (b) If on or before the Release Date, Parent asserts a Claim, then Parent may send to the Stockholders’ Representative and the Escrow Agent a
written notice (a “Claim Notice”) (i) describing in brief the basis for its Claim, and (ii) setting forth a request to release Escrow Assets to it in the amount of the Indemnifiable Losses. If the exact amount of
Indemnifiable Losses associated with any Claim has not been fixed, then Parent’s Claim Notice shall specify a reasonable estimate of the Indemnifiable Losses. 
 (c) Following the receipt by the Escrow Agent of any Claim Notice on or prior to the Release Date: 
  

	 	(i)	if the Escrow Agent receives a written response from the Stockholders’ Representative after their receipt of such a Claim Notice which notice states that the Stockholders’
Representative accept or agree to the Claim or any portion thereof, then the Escrow Agent shall deliver to Parent or its designee, a number of Indemnity Escrow Shares having a Market Value equal to the amount set forth in such Claim Notice (or the
undisputed portion thereof) within ten (10) business days after the Escrow Agent receives the Stockholders’ Representative’s notice of acceptance or agreement; 

  

	 	(ii)	If the Escrow Agent does not receive a written notice of acceptance from the Stockholders’ Representative within fifteen (15) business days after receipt of a Claim
Notice, then Stockholder Representative shall be deemed to have accepted the Claim and the Escrow Agent shall deliver to Parent or its designee Indemnity Escrow Shares (or, if all Indemnity Escrow Shares have been distributed, then other Escrow
Assets) having a Market Value equal to the amount set forth in such Claim Notice within ten (10) business days after the expiration of such fifteen (15) business day period; 

  

	 	(iii)	 If the Escrow Agent receives a written notice from the Stockholders’ Representative disputing all or any portion of the Claim (the “Dispute
Notice”), within the fifteen (15) business day period after receipt of a Claim Notice, then the Escrow Agent shall not distribute any Escrow Assets in respect of the amount in dispute until either (i) the Escrow Agent receives
a certified copy of a final decision of an arbitrator in respect of the amount in dispute and a certificate from Parent indicating that all rights of 

	 	 
appeal have expired and no appeal has been filed or there is no further right to appeal the arbitration award, (ii) the Escrow Agent receives a
certified copy of a judgment in respect of the amount in dispute issued by a court of competent jurisdiction and a certificate from Parent indicating that all rights of appeal have expired and no appeal has been filed or there is no further right to
appeal the judgment, or (iii) the Escrow Agent receives a joint written direction with respect to the settlement of the amount in dispute signed by the Stockholders’ Representative and an officer of Parent (each of the resolutions
referenced in (i), (ii) and (iii) above shall be referred to herein as a “Final Resolution”). Within five (5) business days after the receipt of a Final Resolution, the Escrow Agent shall deliver to Parent or
its designee Indemnity Escrow Shares (or, if all Indemnity Escrow Shares have been distributed, then other Escrow Assets) having a Market Value equal to the amount set forth in such Final Resolution. 

 (d) If, on or prior to the Release Date, the Escrow Agent has received a Claim Notice or Claim Notices and all of the related Claims have either been
accepted (or deemed accepted) by the Stockholders’ Representative or resolved by Final Resolution and the related Indemnity Escrow Shares have been distributed, then the Escrow Agent shall distribute to the Indemnifying Stockholders, within
five days after the Release Date, the remaining portion, if any, of the 1,000,000 Indemnity Escrow Shares which would have been released to the Indemnifying Stockholders on the Release Date had no Claims been made. In each case provided in this
Section 6d., Indemnity Escrow Shares will be distributed to the Indemnifying Stockholders in proportion to their relative Indemnity Escrow Shares as set forth on Schedule A attached to this Escrow Agreement. 
 (e) “Market Value” means, as to the Indemnity Escrow Shares, the average of the closing sales price per share of Parent Common
Stock on the OTC Bulletin Board (or other applicable market on which shares of Parent Common Stock are traded or quoted, if not the OTC Bulletin Board) for the ten (10) trading days immediately preceding: (i) the date on which the
Indemnifying Stockholders notify the Escrow Agent that they have no objection to a Claim in accordance with Section 6c(i), if applicable, (ii) the date on which the ten day period described in Section 6c(ii) expires, if applicable, or
(iii) the date on which a Final Resolution is delivered to the Escrow Agent in accordance with Section 6c(iii), if applicable. In each case, Parent shall calculate and deliver the Market Value computation to the Escrow Agent promptly
following the occurrence of any of the events described in clause (i) through (iii) above. As to any Escrow Assets other than Indemnity Escrow Shares, and as to Indemnity Escrow Shares to the extent not traded or quoted on any market, the
Market Value shall be the value determined by a Final Resolution. 
 (f) If Parent is entitled to any distribution of less than all remaining
Indemnity Escrow Shares in accordance with this Section 6, then (i) Escrow Agent shall deliver the certificates representing the Indemnity Escrow Shares to Parent and Parent shall be responsible 

 
for exchanging the certificates delivered to it and returning to the Escrow Agent certificates evidencing the balance of the Indemnity Escrow Shares that
were not required to be delivered to Parent; and (ii) the shares to be surrendered to Parent shall be allocated from among the shares of the Indemnifying Stockholders pro rata based upon their relative number of Indemnity Escrow Shares as set
forth on Schedule A attached to this Escrow Agreement. 
 7. Escrow Termination. This Escrow Agreement shall terminate and
cease to be of any further force and effect (except as otherwise provided in Section 8f) when the Escrow Agent shall have disposed of all of the Escrow Assets according to this Escrow Agreement (including the deposit of the Escrow Assets with a
court of competent jurisdiction). 
 8. Responsibility and Liability of the Escrow Agent. 
 (a) Duties Limited. The duties of the Escrow Agent hereunder shall be entirely administrative and not discretionary, and the Escrow Agent does not
and shall not have any interest in the Escrow Assets. The Escrow Agent’s duties shall be limited to those expressly set forth herein. 
 (b) Reliance. The Escrow Agent may rely upon, and shall not be liable to the parties for acting or refraining from acting upon, any written notice, instruction, certificate, request, consent or other instrument (“Written
Evidence”) furnished to it in connection with its duties as the Escrow Agent and believed by the Escrow Agent to be genuine. The Escrow Agent may rely on Written Evidence not only as to the due execution, validity and effectiveness
thereof but also as to the truth and accuracy of the information contained therein. The Escrow Agent may assume that any person purporting to give any Written Evidence in connection with the provisions hereof has been duly authorized to do so or is
otherwise the proper party or parties. The Escrow Agent may rely on the contents of any Written Evidence of any court, arbitrator or party without any liability therefor. The Escrow Agent shall not be required to determine the merits of any claim of
either party in performing its duties hereunder. 
 (c) No Liability. The Escrow Agent shall not be liable or responsible for any
actions taken by it in good faith. The Escrow Agent’s duties and responsibilities are that of a custodian of the Escrow Assets. The Escrow Agent shall have no liability to any third party as a result of any acts taken or omissions made by the
Escrow Agent in the performance in accordance with this Escrow Agreement of its duties hereunder and no person shall have any rights as a third party beneficiary with respect to this Escrow Agreement. As to any legal questions arising in connection
with the Escrow Agent’s performance of its duties and responsibilities hereunder, the Escrow Agent may consult or obtain opinions from legal counsel selected by it, and the Escrow Agent shall be free from any liability for acting in reliance in
good faith on such advice of counsel. The Escrow Agent shall not be bound by any notice of, or demand with respect to, any waiver, modification, amendment, termination, or rescission of the provisions of this Escrow Agreement unless such notice or
demand is received by the Escrow Agent in writing and has been signed by both Parent and Stockholders’ Representative and, if the Escrow Agent’s duties or responsibilities hereunder are affected, unless the Escrow Agent shall have given
its express written consent thereto. 

 (d) Waiver. Parent and Stockholders’ Representative each hereby waives any suit, claim,
demand or cause of action of any kind which either may have or may assert against the Escrow Agent arising out of or relating to acceptance or performance of the Escrow Agent’s duties hereunder, unless such suit, claim, demand or cause of
action is based upon a claim of the willful neglect, gross negligence or bad faith of the Escrow Agent. 
 (e) Risk of Investment Not the
Escrow Agent’s. Any loss or decline in value of any Escrow Assets is the responsibility of the Indemnifying Stockholders and Parent and not the Escrow Agent. 
 (f) Indemnification. Parent and the Indemnifying Stockholders shall indemnify the Escrow Agent and its officers, directors and employees against all taxes, liabilities, damages, losses, actions, proceedings,
costs, claims and demands in respect of any matter or thing performed by the Escrow Agent, its officers, directors or employees pursuant to this Escrow Agreement (with Parent, on the one hand, and the Indemnifying Stockholders, on the other hand,
being responsible for one-half (1/2) of the indemnity obligation pursuant to this Section), other than taxes, liabilities, damages, losses, actions, proceedings, costs, claims or demands arising from a breach of this Escrow Agreement by the
Escrow Agent or negligence or willful misconduct on the part of the Escrow Agent, its officers, directors and employees. The indemnity contained herein shall survive the termination or expiration of this Escrow Agreement. 
 (g) Resignation or Termination of the Escrow Agent; Appointment of Successor. The Escrow Agent may resign and be discharged from its duties and
obligations hereunder for any reason. Such resignation shall be made by giving at least thirty (30) days prior written notice of such resignation to Parent and Stockholders’ Representative, specifying the date on which such resignation
shall take effect. Stockholders’ Representative and Parent shall also have the right, by mutual agreement, to terminate the appointment of the Escrow Agent hereunder by giving to it notice of such termination, in a writing signed by both
Stockholders’ Representative and Parent, specifying the date on which such termination shall take effect and designating a successor Escrow Agent. In any such event, Parent and Stockholders’ Representative shall, by mutual agreement,
approve and designate a successor Escrow Agent to such resigning or terminated Escrow Agent. In the event of the Escrow Agent’s intended resignation, if Parent and Stockholders’ Representative cannot agree to a successor Escrow Agent at
least ten days before the effective date of such resignation, the Escrow Agent may deposit the Escrow Assets with a court of competent jurisdiction or any commercial bank or trust company selected by it that agrees to be bound by this Escrow
Agreement. Any successor Escrow Agent shall execute and deliver to the Escrow Agent then serving a written instrument accepting the appointment and agreeing to the terms of this Escrow Agreement. Upon receipt thereof from such successor Escrow
Agent, all Escrow Assets shall be turned over and delivered to such successor Escrow Agent who shall thereupon be bound by all of the provisions hereof as if an original signature hereto, and the Escrow Agent shall be thereafter released of all
further obligations and liability relating to the Escrow Assets arising after the date of such substitution. No resignation or removal of the Escrow Agent shall be effective until the acceptance of appointment by the successor the Escrow Agent in
the manner provided above. 

 h. Escrow Agent as Counsel to Parent. The parties acknowledge that Escrow Agent has been and will
continue to be counsel to Parent and nothing herein shall disqualify Escrow Agent from representing Parent in connection with (i) the making or performance of this Escrow Agreement, (ii) in connection with any disputes arising under or as
a result of this Escrow Agreement or (iii) in connection with any other matters, any and all objections to such representation are hereby irrevocably waived. 
 9. Notices. All notices and other communications under this Escrow Agreement shall be in writing and shall be deemed given when delivered personally, one business day after having been dispatched by a
nationally recognized overnight courier service or when sent via facsimile (with acknowledgement of complete transmission) to the parties at the following addresses (or at such other address for a party as is specified by like notice): 

 

	 	(i)	if to Parent, to: 

 Synova
Healthcare Group, Inc. 
 1400 N. Providence Road 
 Suite 6010, Building II 
 Media, Pennsylvania 19063 
 Attention: Stephen King, CEO 
 Facsimile No.: 610. 565.7081 
 Telephone No: 610.565.7080 
 with a copy (which shall not constitute notice) to:

 Blank Rome LLP 
 One Logan Square 
 Philadelphia, Pennsylvania 19103-6998 
 Attention: Alan L. Zeiger, Esq. 
 Facsimile: 215.832.5754 
 Telephone No.: 215.569.5754 
  

	 	(ii)	if to the Escrow Agent, to: 

 Blank Rome LLP 
 One Logan Square 
 Philadelphia, Pennsylvania 19103-6998 
 Attention: Alan L. Zeiger, Esq. 
 Facsimile: 215.832.5754 
 Telephone No.: 215.569.5754 
  

	 	(iii)	if to the Stockholders’ Representative, to: 

 George Votis 
 c/o Galt Industries, Inc. 
 655 Madison Avenue, 20th Floor 

 New York, NY 10021 
 Facsimile No.: 
 Telephone No.: 
 with a copy (which shall not constitute notice) to: 
 Goodwin Procter 
 599 Lexington Avenue 
 New York, NY 10022 
 Attention: Joel Wagman, Esq. 
 Facsimile No.: 212.355.3333 
 Telephone No.: 212.813.8862 
 10. Fees and Expenses of the Escrow Agent. Parent shall pay all of the Escrow Agent’s out-of-pocket administrative fees, costs and expenses
in connection with its services as the Escrow Agent hereunder. 
 11. Modification or Amendment. This Escrow Agreement may be amended
only by an instrument in writing executed and delivered on behalf of each of the parties hereto. 
 12. Governing Law. This Escrow
Agreement, and all disputes, controversies, claims or other matters arising among the parties to this Escrow Agreement, shall be governed by and construed and interpreted in accordance with the laws of the State of Delaware, irrespective of the
choice of laws principles of the State of Delaware, as to all matters, including matters of validity, construction, effect, enforceability, performance and remedies. 
 13. Assignment. This Escrow Agreement may be assigned by any party only with the consent of the other parties, except that Parent can assign its rights hereunder to any Person to whom or which Parent’s
rights under the Merger Agreement are permitted to be and have been assigned. 
 14. Interpretation. This Escrow Agreement shall be
interpreted in a manner consistent with the principles set forth in Section 8.3 of the Merger Agreement. 
 15. Jurisdiction; Venue;
Waiver of Jury Trial. In any action between or among any of the parties, whether arising out of this Escrow Agreement or otherwise (i) each of the parties irrevocably consents to the exclusive jurisdiction and venue of the state courts
located in the State of Delaware or the U.S. District Court for the District of Delaware; (ii) if any such action is commenced in a state court, then, subject to applicable law, no party shall object to the removal of such action to the U.S.
District Court for the District of Delaware; (iii) EACH OF THE PARTIES IRREVOCABLY WAIVES THE RIGHT TO TRIAL BY JURY. 
 16.
Counterparts. This Escrow Agreement may be executed in any number of separate counterparts, each of which shall be deemed to be an original, but which together shall constitute one and the same instrument 

 IN WITNESS WHEREOF, the parties hereto have executed and delivered this Escrow Agreement on the date and
year first written above. 
  

			
	SYNOVA HEALTHCARE GROUP, INC.
		
	By:	 	 /s/ Stephen King

	Name:	 	Stephen King
	Title:	 	CEO
	
	STOCKHOLDERS’ REPRESENTATIVE:
	
	 /s/ George Votis

	George Votis
	
	STOCKHOLDERS:
	  
 GALT INDUSTRIES, INC.

		
	By:	 	 /s/ George Votis

	Name:	 	G. T. Votis
	Title:	 	Chairman
	
	 /s/ Gene Detroyer

	Gene Detroyer
	
	 /s/ Robert Staab

	Robert Staab
	
	ESCROW AGENT:
	  
 BLANK ROME LLP

		
	By:	 	 /s/ Alan L. Zeiger

	Name:	 	Alan L. Zeiger
	Title:	 	Partner

 Schedule A 
 Indemnifying Stockholders List With Number of Shares and Addresses for Distribution 
  

			
	 Stockholders and Addresses
	  	Number of Shares
	 Galt Industries, Inc.
 655 Madison Avenue, 20th Floor
 New York, NY 10021
	  	333,333.33
		
	 Gene Detroyer
 357 East 57th Street, Apt. 14B
 New York, NY
10022
	  	333,333.33
		
	 Robert Staab
 30 Neck Road
 Old Lyne, CT 06372
	  	333,333.33

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00117-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00117-of-00352.parquet"}]]